Scientists at ORNL used their expertise in quantum biology, artificial intelligence and bioengineering to improve how CRISPR Cas9 genome editing tools work on organisms like microbes that can be modified to produce renewable fuels and chemicals.
Innovations in artificial intelligence are rapidly shaping our world, from virtual assistants and chatbots to self-driving cars and automated manufacturing.
The Oak Ridge Leadership Computing Facility’s Matt Sieger has been named the project director for the OLCF-6 effort. This next OLCF undertaking will plan and build a world-class successor to the OLCF’s still-new exascale system, Frontier.
With the world’s first exascale supercomputing system now open to full user operations, research teams are harnessing Frontier’s power and speed to tackle some of the most challenging problems in modern science.
ORNL has named Michael Parks director of the Computer Science and Mathematics Division within ORNL’s Computing and Computational Sciences Directorate. His hiring became effective March 13.
ORNL has entered a strategic research partnership with the United Kingdom Atomic Energy Authority, or UKAEA, to investigate how different types of materials behave under the influence of high-energy neutron sources. The $4 million project is part of UKAEA's roadmap program, which aims to produce electricity from fusion.
Gina Tourassi has been appointed as director of the National Center for Computational Sciences, a division of the Computing and Computational Sciences Directorate at Oak Ridge National Laboratory.
OAK RIDGE, Tenn., May 7, 2019—The U.S. Department of Energy today announced a contract with Cray Inc. to build the Frontier supercomputer at Oak Ridge National Laboratory, which is anticipated to debut in 2021 as the world’s most powerful computer with a performance of greater than 1.5 exaflops.
OAK RIDGE, Tenn., May 7, 2019—Energy Secretary Rick Perry, Congressman Chuck Fleischmann and lab officials today broke ground on a multipurpose research facility that will provide state-of-the-art laboratory space
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.